Category: #Publications

  • A summary of major scientific publishers’ guidelines on the use of LLMs and other genAI in research articles

    As more and more authors turn to large language models (LLMs) and other generative artificial intelligence (genAI) tools for writing support, the scientific publishers have responded with a patchwork of guidance that varies considerably across journals and publishers. Here, we rise to the challenge of navigating this complex environment in an attempt to summarise very…

  • Communicating the safety profile of an oncology drug

    At the centre of any communication on the adverse event (AE) profile of a new drug lies a fundamental principle: no medication is ever completely safe. Every drug, from over-the-counter paracetamol to cutting-edge biologics, is associated with a specific set of AEs listed on the package insert. Having said that, anticancer drugs exist in a…

  • Publication planning

    A pharma-sponsored publication plan is an integral part of a scientific communications plan, which in turn is a part of the wider Medical Affairs strategy. It is also a living document that contains publication strategy and objectives, key scientific communication points and publication tactics: where, when and how the data will be published. Of course,…

  • CONSORT and SPIRIT update 2025

    📢 Attention all medical writers, publication professionals and clinical researchers! 📢 You have been waiting for 15 years, and now it’s there! 🏆 Yes, you have guessed right – we are talking about the CONSORT 2025 statement simultaneously published yesterday in The BMJ, JAMA, The Lancet, Nature Medicine and PLOS Medicine.  ⭐ The Consolidated Standards…

  • Reporting on race and ethnicity

    One of the recent hot topics in medical research is the role of race and ethnicity in health disparities. If you look on PubMed, you will find tons of literature describing how race and ethnicity affect:🫀 life expectancy⚕️ access to quality medical care💉 healthcare hesitancy🏥 clinical trial recruitment Many pharmaceutical companies now invest in research…